Clinical Trial Update: Efficacy and Safety Study of ABT-436 in Major Depressive Disorder [Phase 2]

View source ↗

Summary

The Phase 2 efficacy and safety trial of ABT-436 for major depressive disorder has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• ABT-436

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Major Depressive Disorder | Phase 2 | Status: TERMINATED